Cassava Sciences to rebrand to Filana Therapeutics
Source: SeekingAlpha
2026-03-10 08:09:34 ET
More on Cassava Sciences
- Cassava says DoJ has ended probe into research misconduct
- Cassava Sciences to pay $31.25M to settle securities class action suit
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences
- Financial information for Cassava Sciences
Read the full article on Seeking Alpha
For further details see:
Cassava Sciences to rebrand to Filana Therapeutics
Cassava Sciences Inc.
NASDAQ: SAVA
SAVA Trading
15.14% G/L:
$2.395 Last:
1,546,293 Volume:
$2.19 Open:
SAVA Latest News
January 13, 2026 08:00:00 am
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease
December 24, 2025 11:51:00 am
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
SAVA Stock Data
$106,035,832
47,148,506
2.07%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Austin
